Mycobacterium tuberculosis multiple enzymes and macromolecular targets (MTB targets)

Mycobacterium tuberculosis (Mtb) represents a complex array of therapeutic targets essential for the survival and pathogenesis of the bacterium responsible for tuberculosis (TB). This collective target profile includes enzymes involved in cell wall synthesis, such as InhA (targeted by isoniazid) and Arabinosyltransferase (targeted by ethambutol), as well as macromolecular complexes like the 30S ribosome and RNA polymerase, which are targeted by aminoglycosides and rifamycins respectively [1][2]. Additionally, newer therapeutic strategies focus on energy metabolism, specifically the mycobacterial ATP synthase inhibited by bedaquiline [3]. The pathogen's ability to enter a latent or persistent state necessitates drugs that can penetrate granulomas and remain active against non-replicating bacilli [4]. Due to the high rate of spontaneous mutations, Mtb is typically treated with a combination of drugs to ensure that multiple essential pathways are inhibited simultaneously. This multi-target approach is critical for reducing the likelihood of developing multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains [5]. Understanding the interplay between these various macromolecular targets is essential for the design of shortened, more effective treatment regimens.

Other names

M. tuberculosis proteomeMTB drug targetsMycobacterium tuberculosis whole cell targets

Drugs targeting this collective group act through various mechanisms, including the inhibition of mycolic acid synthesis (isoniazid), inhibition of DNA-dependent RNA polymerase (rifampicin), inhibition of ATP synthase (bedaquiline), and disruption of the 30S ribosomal subunit (aminoglycosides) [2][3][5].